primary rat cortical neuron culture (Charles River Laboratories)
Structured Review
![DIV8 <t>primary</t> <t>rat</t> <t>cortical</t> <t>neurons</t> were treated with vehicle (Control, n = 4), 1 μM of SKF38393 (D1 dopamine receptor agonist, n = 4) and/or 10 nM of SCH23390 (D1 dopamine receptor antagonist n = 5) for 1.5 h. (A) Schematic shows hnRNP H and its quasi-RNA recognition motifs (qRRMs) and glycine-rich domains (GYR and GY). The red “Y” markings indicate the relative antibody epitopes in the N-domain or C-domain regions of hnRNP H. (B,C) ICC and intensity analysis revealed a significant increase in C-domain staining of nuclear hnRNP H following 1 μM SKF38393 [unpaired Student’s t-test, t6 = −4.94, *p = 0.003] that was blocked by co-administration of 1 μM SKF38393 and 10 nM SCH23390 [unpaired Student’s t-test, t7 = −0.34, p = 0.74]. (D) No significant difference was found in N-domain immunoreactivity of nuclear hnRNP H following 1 μM SKF38393 treatment [unpaired Student’s t-test, t6 = −1.12, p = 0.30]. (E) There was an effect of treatment on C-domain staining of hnRNP H [One-way ANOVA, F2,6 = 20.38, p < 0.001, n = 3 per condition]. SKF38393-induced increase in hnRNP H nuclear immunofluorescence was reduced in the present of the blocking peptide [post-hoc Bonferroni correction for Control vs SKF+blocking peptide: t4 = 5.849; *p = 0.004]. A significant increase in C-domain staining of nuclear hnRNP H following 1 μM SKF38393 [post-hoc Bonferroni correction for Control vs SKF: t4 = −3.454; *p = 0.025]. Black bar = Control; white bar = SKF treatment. Images were obtained on a Zeiss AxioObserver microscope with the 20X objective under uniform settings. Scale bars represent 40 μm.](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_0092/pmc06330092/pmc06330092__nihms-996796-f0001.jpg)
Primary Rat Cortical Neuron Culture, supplied by Charles River Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/primary rat cortical neuron culture/product/Charles River Laboratories
Average 90 stars, based on 1 article reviews
Images
1) Product Images from "Changes in neuronal immunofluorescence in the C- versus N-terminal domains of hnRNP H following D1 dopamine receptor activation"
Article Title: Changes in neuronal immunofluorescence in the C- versus N-terminal domains of hnRNP H following D1 dopamine receptor activation
Journal: Neuroscience letters
doi: 10.1016/j.neulet.2018.07.015
Figure Legend Snippet: DIV8 primary rat cortical neurons were treated with vehicle (Control, n = 4), 1 μM of SKF38393 (D1 dopamine receptor agonist, n = 4) and/or 10 nM of SCH23390 (D1 dopamine receptor antagonist n = 5) for 1.5 h. (A) Schematic shows hnRNP H and its quasi-RNA recognition motifs (qRRMs) and glycine-rich domains (GYR and GY). The red “Y” markings indicate the relative antibody epitopes in the N-domain or C-domain regions of hnRNP H. (B,C) ICC and intensity analysis revealed a significant increase in C-domain staining of nuclear hnRNP H following 1 μM SKF38393 [unpaired Student’s t-test, t6 = −4.94, *p = 0.003] that was blocked by co-administration of 1 μM SKF38393 and 10 nM SCH23390 [unpaired Student’s t-test, t7 = −0.34, p = 0.74]. (D) No significant difference was found in N-domain immunoreactivity of nuclear hnRNP H following 1 μM SKF38393 treatment [unpaired Student’s t-test, t6 = −1.12, p = 0.30]. (E) There was an effect of treatment on C-domain staining of hnRNP H [One-way ANOVA, F2,6 = 20.38, p < 0.001, n = 3 per condition]. SKF38393-induced increase in hnRNP H nuclear immunofluorescence was reduced in the present of the blocking peptide [post-hoc Bonferroni correction for Control vs SKF+blocking peptide: t4 = 5.849; *p = 0.004]. A significant increase in C-domain staining of nuclear hnRNP H following 1 μM SKF38393 [post-hoc Bonferroni correction for Control vs SKF: t4 = −3.454; *p = 0.025]. Black bar = Control; white bar = SKF treatment. Images were obtained on a Zeiss AxioObserver microscope with the 20X objective under uniform settings. Scale bars represent 40 μm.
Techniques Used: Control, Staining, Immunofluorescence, Blocking Assay, Microscopy
Figure Legend Snippet: DIV8 primary rat cortical neurons were treated with media (Control, n = 4) or 1 μM of SKF38393 (D1 dopamine receptor agonist, n = 4) for 1.5 h. (A) Schematic shows hnRNP H domains and the red “Y” marking indicates the relative antibody epitopes in the C-domain regions of hnRNP H. (B) Merged images showing co-localization of hnRNP H with NeuN (neuronal marker) and DAPI (nuclear marker). Images from individual channel are shown in Fig S5. hnRNP H staining was localized to the nucleus and no cytoplasmic localization of hnRNP H was detected. ICC and intensity analysis revealed a significant increase in C-domain staining of nuclear hnRNP H following 1 μM SKF38393 for NeuN-positive and hnRNP H-positive neurons (unpaired Student’s t-test, t6 = −5.58, *p < 0.01). (C) There was co-localized staining of hnRNP H with NeuN-positive neuronal staining and no detectable staining of hnRNP H staining in non-neuronal cells. No significant differences in percentage of NeuN/hnRNP H-positive cells [unpaired Student’s t-test, t6 = −0.052, p = 0.96] or non-NeuN cells [unpaired Student’s t-test, t6 = −0.052, p = 0.96] were noted between treatment conditions. Black bar = Control; white bar = SKF treatment. Images were obtained on a Zeiss AxioObserver microscope with the 63X objective under uniform settings. Scale bars represent 15 μm.
Techniques Used: Control, Marker, Staining, Microscopy
Figure Legend Snippet: DIV8 primary rat cortical neurons were treated with vehicle (Control, n = 4) or 1 μM of SKF38393 (D1 dopamine receptor agonist, n = 4) for 1.5 h. (A) qPCR analysis revealed a small decrease in Hnrnph1 mRNA (top left) [Exon 4–5: unpaired Student’s t-test, t6 = 2.866, *p = 0.03; Exon13–15: unpaired Student’s t-test, t6 = 3.367, *p=0.02] or Hnrnph2 mRNA (top right) [unpaired Student’s t-test, t6 = 2.432, p = 0.051]. (B) Immunoblot analysis of fractionated samples indicated no significant change in hnRNP H protein levels in the nucleus (Nu) or cytoplasm (Cy), as detected by either C-domain (left) or N-domain (right) antibodies. Two-way ANOVA with Cellular Compartment and Treatment as factors revealed a significant effect of Cellular Compartment [C-domain: F(1,12) = 51.45, p = 1.13 × 10−5; N-domain: F(1,12) = 123.52, p = 1.13 × 10−7], no significant effect of Treatment [C-domain: F(1,12) = 1.06, p = 0.32; N-domain: F(1,12) = 4.11, p = 0.07], and no interaction [C-domain: F(1,12) = 0.26, p = 0.62; N-domain: F(1,12) = 2.66, p = 0.13]. Successful nuclear and cytoplasmic fractionation was confirmed by CREB and HSP90. For either C- and N-domain immunoblot study: Control: n = 4, 1 μM SKF38393: n = 4. Black bar = Control; white bar = SKF treatment.
Techniques Used: Control, Western Blot, Fractionation

